Data from the 2003–2019 Medical Expenditure Panel Survey (MEPS) showed that NH Black adults consistently had the lowest utilization of medications used in the management of diabetes and obesity, such as glucagon-like peptide-1 receptor agonists (GLP-1 RA), among all racial groups. This evidence concerns the gene GLP1R and obesity disorder.